numares AG

11 articles about numares AG

• FDA Clears Numares Health Cardiovascular Diagnostic Test and Core Technology Platform

  7/25/2023

  The US Food and Drug Administration has cleared a Numares Health test, the AXINON® LDL-p Test System, as a new tool physicians can use to measure lipoproteins for patients at risk for cardiovascular disease.

• numares Appoints Dr. Gregory Heath As New Member of the Supervisory Board and Submits an Additional Test to the FDA

  12/15/2021

  numares Appoints Dr. Gregory Heath As New Member of the Supervisory Board and Submits an Additional Test to the FDA.

• numares and Oxford University sign exclusive license agreement for novel multi-marker diagnostics in multiple sclerosis

  10/28/2021

  Leading NMR diagnostics company numares AG announced that the company signed an exclusive licence agreement with Oxford University Innovation.

• numares announces FDA 510(k) Submission of AXINON System®, a NMR platform for metabolomics-based, AI-driven Diagnostics

  3/24/2021

  numares announces FDA 510(k) Submission of AXINON System ® , a NMR platform for metabolomics-based, AI-driven Diagnostics

• numares’ Novel GFR Equation Allows Accurate Assessment of Renal Insufficiency in Proof of Concept

  2/25/2021

  Leading NMR diagnostics company numares recently published data showing that its novel, multi-marker approach to assess kidney function allowed for a more precise estimation of glomerular filtration rate by a simple serum test.

• numares and Bruker Sign Agreement to Enable Advanced Metabolomics-based Clinical Diagnostics

  1/21/2021

  Leading metabolomics based diagnostics company numares AG and analytical instrumentation and solution provider Bruker Corporation have signed an agreement to collaborate to bring new diagnostics tests utilizing NMR to the laboratory market for unmet medical needs.

• numares’ Novel Multi-marker Kidney Function Testing Shows Promising Results in US Validation Study

  12/15/2020

  numares ’ Novel Multi-marker Kidney Function Testing Shows Promising Results in US Validation Study - Based on US clinical samples, leading NMR diagnostics company numares successfully finished validation of a multi-marker serum test of kidney function - GFR NMR uses a defined model for glomerular filtration rate (GFR) equation to assess kidney function, comprised of the analysis of several metabolites in serum together with age and sex.

• numares Announces Winton Gibbons as New President of US Subsidiary

  6/8/2020

  numares appoints Winton Gibbons, as new president of its US subsidiary, numares Group Corp., effective of June 1 st , 2020. Mr. Gibbons will further strengthen commercialization of numares’ products, and help expand the existing network of collaboration partners and investors. This press release features multimedia. View the full release here:

• numares Elects Kathy L. Bates as New Member of the Supervisory Board

  9/10/2019

  numares appoints Kathy L. Bates, MBA, as new member of the Supervisory Board with immediate effect. Ms. Bates is Senior Director, Laboratory Services and Partnership Development at Mayo Clinic, in Rochester, Minnesota.

• numares Focuses on Possibilities of Artificial Intelligence - Joint IVD Test Development With University of Oxford

  10/24/2017

  The use of metabolomic constellations instead of individual biomarkers is becoming more and more the focus of in-vitro diagnostics in order to provide information to the treating physicians for diagnostic questions which have not yet been clarified.

• numares AG Achieves Key Milestone: Identifies Candidate Metabolomic Network For Bladder Cancer Diagnostics

  7/13/2017